Literature DB >> 31815742

Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response.

Mireia Uribe-Herranz1,2, Stavros Rafail2, Silvia Beghi1, Luis Gil-de-Gómez1, Ioannis Verginadis1, Kyle Bittinger3, Sergey Pustylnikov1, Stefano Pierini1,2, Renzo Perales-Linares1, Ian A Blair4, Clementina A Mesaros4, Nathaniel W Snyder5, Frederic Bushman6, Constantinos Koumenis1, Andrea Facciabene1,2.   

Abstract

Alterations in gut microbiota impact the pathophysiology of several diseases, including cancer. Radiotherapy (RT), an established curative and palliative cancer treatment, exerts potent immune modulatory effects, inducing tumor-associated antigen (TAA) cross-priming with antitumor CD8+ T cell elicitation and abscopal effects. We tested whether the gut microbiota modulates antitumor immune response following RT distal to the gut. Vancomycin, an antibiotic that acts mainly on gram-positive bacteria and is restricted to the gut, potentiated the RT-induced antitumor immune response and tumor growth inhibition. This synergy was dependent on TAA cross presentation to cytolytic CD8+ T cells and on IFN-γ. Notably, butyrate, a metabolite produced by the vancomycin-depleted gut bacteria, abrogated the vancomycin effect. In conclusion, depletion of vancomycin-sensitive bacteria enhances the antitumor activity of RT, which has important clinical ramifications.

Entities:  

Keywords:  Antigen presentation; Dendritic cells; Immunology; Oncology; Radiation therapy

Mesh:

Substances:

Year:  2020        PMID: 31815742      PMCID: PMC6934221          DOI: 10.1172/JCI124332

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   19.456


  76 in total

Review 1.  Host-gut microbiota metabolic interactions.

Authors:  Jeremy K Nicholson; Elaine Holmes; James Kinross; Remy Burcelin; Glenn Gibson; Wei Jia; Sven Pettersson
Journal:  Science       Date:  2012-06-06       Impact factor: 47.728

Review 2.  Microbiome and Anticancer Immunosurveillance.

Authors:  Laurence Zitvogel; Maha Ayyoub; Bertrand Routy; Guido Kroemer
Journal:  Cell       Date:  2016-04-07       Impact factor: 41.582

3.  Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes.

Authors:  P T Mehrotra; D Wu; J A Crim; H S Mostowski; J P Siegel
Journal:  J Immunol       Date:  1993-09-01       Impact factor: 5.422

4.  Induction of intestinal Th17 cells by segmented filamentous bacteria.

Authors:  Ivaylo I Ivanov; Koji Atarashi; Nicolas Manel; Eoin L Brodie; Tatsuichiro Shima; Ulas Karaoz; Dongguang Wei; Katherine C Goldfarb; Clark A Santee; Susan V Lynch; Takeshi Tanoue; Akemi Imaoka; Kikuji Itoh; Kiyoshi Takeda; Yoshinori Umesaki; Kenya Honda; Dan R Littman
Journal:  Cell       Date:  2009-10-30       Impact factor: 41.582

5.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

Authors:  K Y Lin; F G Guarnieri; K F Staveley-O'Carroll; H I Levitsky; J T August; D M Pardoll; T C Wu
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

6.  Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.

Authors:  Yuki Muroyama; Thomas R Nirschl; Christina M Kochel; Zoila Lopez-Bujanda; Debebe Theodros; Wendy Mao; Maria A Carrera-Haro; Ali Ghasemzadeh; Ariel E Marciscano; Esteban Velarde; Ada J Tam; Christopher J Thoburn; Muniza Uddin; Alan K Meeker; Robert A Anders; Drew M Pardoll; Charles G Drake
Journal:  Cancer Immunol Res       Date:  2017-10-02       Impact factor: 11.151

Review 7.  Pharmacokinetics of vancomycin.

Authors:  R C Moellering
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

Review 8.  Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy.

Authors:  Maxim Shevtsov; Hiro Sato; Gabriele Multhoff; Atsushi Shibata
Journal:  Front Oncol       Date:  2019-03-19       Impact factor: 6.244

9.  Metastatic potential of B16 melanoma cells after in vitro selection for organ-specific adherence.

Authors:  P A Netland; B R Zetter
Journal:  J Cell Biol       Date:  1985-09       Impact factor: 10.539

10.  Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death.

Authors:  Encouse B Golden; Derek Frances; Ilenia Pellicciotta; Sandra Demaria; Mary Helen Barcellos-Hoff; Silvia C Formenti
Journal:  Oncoimmunology       Date:  2014-04-25       Impact factor: 8.110

View more
  44 in total

1.  Vancomycin Pretreatment on MPTP-Induced Parkinson's Disease Mice Exerts Neuroprotection by Suppressing Inflammation Both in Brain and Gut.

Authors:  Chun Cui; Hui Hong; Yun Shi; Yu Zhou; Chen-Meng Qiao; Wei-Jiang Zhao; Li-Ping Zhao; Jian Wu; Wei Quan; Gu-Yu Niu; Yi-Bo Wu; Chao-Sheng Li; Li Cheng; Yan Hong; Yan-Qin Shen
Journal:  J Neuroimmune Pharmacol       Date:  2022-01-29       Impact factor: 4.147

Review 2.  Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients.

Authors:  Selina E Eaton; Justyna Kaczmarek; Daanish Mahmood; Anna M McDiarmid; Alya N Norarfan; Erin G Scott; Chee Kin Then; Hailey Y Tsui; Anne E Kiltie
Journal:  Br J Cancer       Date:  2022-09-29       Impact factor: 9.075

3.  Analysis of Gut Microbiota Signature and Microbe-Disease Progression Associations in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Concurrent Chemoradiotherapy.

Authors:  Yu Xi; FangJie Liu; Bo Qiu; Ying Li; XinQiang Xie; JinYu Guo; Lei Wu; TingTing Liang; DaQuan Wang; Juan Wang; Moutong Chen; Liang Xue; Yu Ding; Jumei Zhang; QingPing Wu; Hui Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-06-01       Impact factor: 6.073

Review 4.  Gut microbiome in gastrointestinal cancer: a friend or foe?

Authors:  Yang Liu; Yoshifumi Baba; Takatsugu Ishimoto; Xi Gu; Jun Zhang; Daichi Nomoto; Kazuo Okadome; Hideo Baba; Peng Qiu
Journal:  Int J Biol Sci       Date:  2022-06-21       Impact factor: 10.750

Review 5.  Gut Microbiome Modulates Response to Cancer Immunotherapy.

Authors:  Md Abdul Wadud Khan; Gabriel Ologun; Reetakshi Arora; Jennifer L McQuade; Jennifer A Wargo
Journal:  Dig Dis Sci       Date:  2020-03       Impact factor: 3.199

6.  Antibiotics impair immunotherapy for urothelial cancer.

Authors:  Lisa Derosa; Laurence Zitvogel
Journal:  Nat Rev Urol       Date:  2020-11       Impact factor: 14.432

Review 7.  The microbiome and human cancer.

Authors:  Gregory D Sepich-Poore; Laurence Zitvogel; Ravid Straussman; Jeff Hasty; Jennifer A Wargo; Rob Knight
Journal:  Science       Date:  2021-03-26       Impact factor: 47.728

Review 8.  Gut Microbiota: Influence on Carcinogenesis and Modulation Strategies by Drug Delivery Systems to Improve Cancer Therapy.

Authors:  Runqi Zhu; Tianqun Lang; Wenlu Yan; Xiao Zhu; Xin Huang; Qi Yin; Yaping Li
Journal:  Adv Sci (Weinh)       Date:  2021-03-09       Impact factor: 16.806

9.  Fecal microbiota composition associates with the capacity of human peripheral blood monocytes to differentiate into immunogenic dendritic cells in vitro.

Authors:  Dušan Radojević; Sergej Tomić; Dušan Mihajlović; Maja Tolinački; Bojan Pavlović; Dragana Vučević; Svetlana Bojić; Nataša Golić; Miodrag Čolić; Jelena Đokić
Journal:  Gut Microbes       Date:  2021 Jan-Dec

10.  Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study.

Authors:  Niloufer Khan; Sarah Lindner; Antonio L C Gomes; Sean M Devlin; Gunjan L Shah; Anthony D Sung; Craig S Sauter; Heather J Landau; Parastoo B Dahi; Miguel-Angel Perales; David J Chung; Alexander M Lesokhin; Anqi Dai; Annelie Clurman; John B Slingerland; Ann E Slingerland; Daniel G Brereton; Paul A Giardina; Molly Maloy; Gabriel K Armijo; Carlos Rondon-Clavo; Emily Fontana; Lauren Bohannon; Sendhilnathan Ramalingam; Amy T Bush; Meagan V Lew; Julia A Messina; Eric Littmann; Ying Taur; Robert R Jenq; Nelson J Chao; Sergio Giralt; Kate A Markey; Eric G Pamer; Marcel R M van den Brink; Jonathan U Peled
Journal:  Blood       Date:  2021-03-18       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.